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Figure 12. Schematic illustration showing the proposed N-alkyl 
interaction sites, A and B in relation to the structure of the 
template molecule (S)-octoclothepin. A is the site proposed to 
be used by the alkyl group in compounds with an N-ethyl sub· 
stituent, while B is the proposed site for an N-benzylsubstituent. 
interaction model proposed by Liljefors and B0ges0, ex-
tending this model to include the important benzamide 
class of DA D-2 receptor antagonists. For benzamides with 
an acyclic amide side chain, the most probable receptor-
bound conformation is the one with an extended alkyl 
substituent. The enantioselectivity of the chirat benzamide 
of type 3 may be rationalized in terms of conformational 
energy differences for the receptor bound enantiomers. 
The N-alkyl substituent of the benzamides is proposed to 
be able to interact with two different sites for the N-alkyl 
substituent. For the benzamides studied in this work, the 
N-benzyl groups of compounds 6 and 12 are proposed to 
interact with one receptor site, while the alkyl group in 
benzamides with a N-ethyl group (compounds 9, 10, and 
11) may interact with the other site. 
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In the search for more selective A2-receptor agonists and on the basis that appropriate substitution at C2 is known 
to impart selectivity for A2 receptors, 2-alkynyladenosines 2a-d were resynthesized and evaluated in radioligand 
binding, adenylate cycla.se, and platelet aggregation studies. Binding of [3H]NECA to A2 receptors of rat striatal 
membranes was inhibited by compounds 2a-d with K1 values ranging from 2.8 to 16.4 nM. 2-Alkynyladenosines 
also exhibited high-affmity binding at solubilized A2 receptors from human platelet membranes. Competition of 
2-alkynyladenosines 2a-d for the antagonist radioligand [3H]DPCPX and for the agonist [8H]CCPA gave K1 values 
in the nanomolar range, and the compounds showed moderate A2 selectivity. In order to improve this selectivity, 
the correaponding 2-alkynyl derivatives of adenosine-5'-N-ethyluronamide 8a-d were synthesized and tested. Al 
expected, the 5'-N-ethyluronamide derivatives retained the A2 affinity whereas the A1 affinity was attenuated, resulting 
in an up to 10-fold increase in A2 selectivity. A similar patternwas observed in adenylate cyclase assays andin 
platelet aggregation studies. A 30- to 45-fold selectivity for platelet A2 receptors compared to A1 receptors was found 
for compounds 8a-c in adenylate cyclase studies. 
Adenosine appears to mediate a wide variety of physi-
ological functions including vasodilatation, vasoconstriction 
in the k.idney, cardiac depression, inhibition of lipolysis, 
inhibition of platelet aggregation, inhibition of lymphocyte 
functions, inhibition of insulin release and potentiation of 
glucagon release in the pancreas, inhibition of neurotran-
smitter release from nerve endings, Stimulation of ster-
oidogenesis, and potentiation of histamine release from 
mast cells. 2 Many of its effects can be attributed to the 
action at receptors located on the cell surface, which are 
mediated by at least two extracellular receptors divided 
into two major subtypes, called A1 and A2• 3 
At A1 receptors the most active analogues are N6-sub-
stituted adenosines, whereas at A2 receptors the most ac-
tive compounds are adenosine-5'-N-alkyluronamides. We 
recently reported the synthesis of N8-substituted 1-de-
azaadenosines,4 and of 2-chloro-N'-cyclopentyladenosine 
(CCPA) which proved to be an agonist with high affinity 
t Universität Heidelberg. 
l Present address: Dept. of Chemistry, MontanaState Univ-
ersity, Bozeman, MT 59717. 
and approximately 10 000-fold selectivity for A1 adenosine 
receptors. 5•8 
(1) A preliminary account of thia work wu presented at the In-
ternational Symposium on Pharmacology of Purinergic Re-
ceptors-IUPHAR Satellite Symposium, Noordwijk (The 
Netherlands), 6-8 July, 1990. 
(2) Stone, T. W. Purine receptora and their pharmacological roles. 
Advances in Drug Research; Academic Preu Limited: New 
York, 1989; Val. 18, pp 291-429. 
(3) (a) Van Calker, D.; Muller, M.; Hamprecht, B. Adenoaine 
regulates via two different type& of receptora the accumulation 
of cyclic AMP in cultured brain cells. J. Neurosci. 1979,33, 
999-1005. (b) Londos, C.; Cooper, D. M. F.; Wolff, J. Sub-
cluaes of externaladenosine receptora. Proc. Natl. Acad. Sei. 
U.S.A. 1980, 77,2661-2664. (c) Daly, J. W. Adenosine recep-
tors: targets for future drugs. J. Med. Chem. 1982, 25, 
197-207. (d) Bumatock, G.; Buckley, N. J. The clusification 
of recepton for adenosine and adenine nucleotidea. In Meth-
ods in Pharmacology. Methods Used in Adenosine Research; 
Paton, D. M., Ed.; Plenum: New York, 1986; Vol. 6, pp 
193-212. (e) Olason, R. A.; Pearaon, J. D. Cardiovascolar 
purinocepton. Physiol. Rev. 1990, 70 (3), 761-846. (f) Ken-
nedy, C. P1- and P2-purinoceptor subtypes: an update. Arch. 
Int. Pharmacodyn. 1990,303, 3~50. 
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Table I. 2-Alkynyl Derivatives of Adenosine (2a-d) and Adenosine-5'-N-ethyluronamide (8a-d) from Scheme I 
compd R chromatog solvent yield,% mp, oco formula11 
2a (CH2)zCHa CHCl3-cCeH12-MeOH 83 118-120C CtaHtsNaO, 
2b (CH2)aCHa 
(78:10:12) 
Ceß8-Ac0Et-Me0H 84 115-117C CteH2tNaO, (60:32:8) 
2c (CH2)4CHa CHCI3-c8H8-Me0H 70 no-n2C C17H23NaO, (60:36:6) 
2d (CH2hCHa CHCl3-MeOH 78 111-113c CtsH26NsO, (90:10) 
Sa (CH2)zCH3 CHC13-c8H1.-Me0H 70 137-139 C11H22NeO, (60:28:12) 
Sb (CH2)aCHa CHC13-MeOH 70 135-137 CtsH2,NaO, (92:8) 
Sc (CH2)4CH3 CHC13-Me0H 65 196-198 CtsH28NeO, (90:10) 
Sd (CH2) 6CHa CHC13-MeOH 68 146-147 CJ{28N80 4 (90:10) 
0 Uncorrected. 11 All compounds had satisfactory C, H, N, microanalyses and were within 0.4% of the theoretical value. All compounds 
exhibited 1H NMR spectra consistent with the assigned structures. c Reference 12b. 
On the other hand, the prototypical A2 agonist adeno-
sine-5'-N-ethyluronamide (NECA) showed little or no A2 
selectivity. 7 In the search for more selective A2 receptor 
agonist8 and on the basis that appropriate substitution at 
C2 is known to impart selectivity for A2 receptors,7- 11 2· 
(4) Cristalli, G.; Grifantini, M.; Vittori, S.; Klotz, K.-N.; Lohse, M. 
J. Adenosine receptor agonists: synthesis and biological 
evaluation of 1-deaza analogues of adenosine derivatives. J. 
Med. Chem. 19S8, 31, 1179-1183. 
(5) Lohse, M. J.; Klotz, K.-N.; Schwabe, U.; Cristalli, G.; Vittori, 
S.; Grifantini, M. 2-Chloro-N8-cyclopentyladenosine: a. highly 
selective agonist at A1 adenosine receptors. Naunyn-Schmie-
deberg's Arch. Pharmacol. 1988, 337, 687~89. 
(6) Klotz, K.-N.; Lohse, M. J.; Schwabe, U.; Cristalli, G.; Vittori, 
S.; Grifantini, M. 2·Chloro-N8-[3H]cyclopentyladenosine 
([3H]CCPA): a high affmity agonist radioligand for A1 aden· 
osine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 
1989,340,679-683. 
(7) Bruns, R. F.; Lu, G. H.; Pugsley, T. A. Characterization of the 
A2 adenosine receptor labeled by [3H]NECA in rat striatal 
membranes. Mol. Pharmacol. 1986,29,331-346. 
(8) Matsuda, A.; Ueda, T. The synthesis, mutagenic and pharma· 
cological activities of 2-carbon-substituted adenosines. Nu-
cleosides Nucleotides 1987, 6, 86-94. 
(9) Ueeda, M.; Thompson, R. D.; Arroyo, L. H.; Olsson, R. A. 
l·Alkozyadenosines: potent and selective agonists at the cor-
onary artery A2 adenosine receptor. J. Med. Chem. 1991, 34, 
1334-1339. 
alkynyladenosines 2a-d12 and the corresponding 2-alkynyl 
derivatives of adenosine-5'-N-ethyluronamide 8a-d-were 
synthesized (Scheme I) and evaluated in radioligand 
binding, adenylate cyclase, and platelet aggregation studies. 
(10) Ueeda, M.; Thompson, R. D.; Arroyo, L. H.; Olsson, R. A. 
2-Aralkoxyadenosines: potent and selective agonists at the 
coronary artery A2 adenosine receptor. J. Med. Chem. 1991, 
34, 134Q-1344. 
(11) (a) Hutchison, A. J.; Webb, R. L.; Oei, H. H.; Ghai, G. R.; 
Zimmerman, M. B.; Williams, M. [8H]CGS 21680, a selective 
A2 adenosine receptor agoniat directly Iabels A2 receptors in rat 
brain. J. Pharmacol. Exp. Ther. 1989, 251, 888-893. (b) 
Hutchison, A. J.; Williams, M.; de Jesus, R.; Yokoyama, R.; 
Oei, H. H.; Ghai, G. R.; Webb, R. L.; Zoganas, H. C.; Stone, G. 
A.; Jarvis, M. F. 2-(Arylalkylamino)adenosine-5'-uronamides: 
a new class of highly selective adenosine A2 receptor ligands. 
J. Med. Chem. 1990, 33, 1919-1924. 
(12) (a) Matsuda, A.; Shinozaki, M.; Miyasaka, T.; Machida, H.; 
Abiru, T. Palladium-catalized cross-coupling of 2-iodo-
adenosine with therminal alkynes: synthesis and biological 
activities of 2-alkynyladenosines. Chem. Pharm. Bull. 19S5, 
33, 1766-1769. (b) Miyasaka, T.; Matsuda, A.; Abiru, T.; Ma· 
chida, H. Antihypertensive agents compriaing 2-alkynyl-
adenosines as active ingredients. Eur. Pat. 0219876A2, 1987. 
(c) Abiru, T.; Yamaguki, T.; Watanabe, Y.; Kogi, K.; Aihara, 
K.; Matsuda, A. The antihypertensive effect of 2-alkynyl-
adenosines and their selective affinity for adenosine A2 recep-
tors. Eur. J. Pharmacol. 1991, 196, 69-76. 
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Chemistry 
The synthesis of 2-alkynyladenosines 2a-d128 and of 
2-alkynyl derivatives of adenosine-5'-N-ethyluronamide 
8a-d was accomplished by the reactions described in 
Scheme I. The synthesis of compounds 2a-d was carried 
out by a modification of the palladium-catalyzed cross-
coupling reaction reported by Matsuda et al.128 Treatment 
of a solution of 2-iodoadenosine (1)18 in dry acetonitrile 
and triethylamine with cuprous iodide, PdC12, triphenyl-
phosphine, and the appropriate terminal alkyne, at room 
temperature for 24 h under an atmosphere of N2, effected 
complete conversion of the iodonucleoside to the alkynyl 
derivatives 2a-d (Table I). 
The synthesis of the NECA derivatives 8a-d was ac-
complished by a similar cross-coupling reaction between 
the appropriate terminal alkynes and the new nucleoside 
N-ethyl-1'-deoxy-1'-(6-amino-2-iodo-9H-purin-9-yl)-ß·D-
ribofuranuronamide (7). 
The synthesis of N-ethyl-1'-deoxy-1'·(6-amino-2-iodo-
9H-purin·9-yl)-ß-n-ribofuranuronamide (7) is reported in 
Scheme I. Reaction at room temperature of 2-iodo-
adenosine (1)13 with acetone in the presence of p-
toluenesulfonic acid as a catalyst gave 6-amino-2-iodo-
9-(2',3' -O-isopropylidene-ß-D-ribofuranosyl)-9H-purine (3). 
This compound was oxidized with KMn04 in aqueous base 
to afford the carboxylic acid 4 in 76% yield. Cleavage of 
the acetonide of 4 with 50% formic acid at 80 °C · gave 
1' -deoxy-1' -(6-amino-2-iodo-9H-purin-9-yl)-ß-n-ribofuran-
uronic acid (5) in 85% yield. 
Treatment of the carboxylic acid 5 with SOC12 in ab-
solute ethanol at room temperature overnight afforded the 
ester 6, which reacted with dry ethylamine at -20 °C to 
give the desired N-ethyl-1'-deoxy-l'-(6-amino-2-iodo-9H-
purin-9-yl)-ß-D-ribofuranuronamide (7). 
Treatment of a solution of compound 7 in dry aceto-
nitrile and triethylamine with cuprous iodide, PdC12, tri-
phenylphosphine, and the appropriate terminal alkyne 
gave the 2-alkynyladenosine-5' -N-ethyluronamide deriva-
tives 8a-d in good yield. 
Biological Evaluation and Diseuseion 
The effects of alkynyladenosines on adenosine receptors 
were tested using both radioligand binding techniques and 
functional assays. Affmities for A2 receptors were deter-
mined in radioligand competition assays for the receptors 
of rat striatum and human platelets using [3H]NECA as 
the radioligand and .N8-cyclopentyladenosine (CPA) in 
order to saturate A1 receptors. To allow determination of 
affinities for platelet A2 receptors, the receptors were 
separated from nonreceptor binding sites by chromato-
graphic procedures as described.14 Affinities for A1 re-
ceptors were determined in radioligand competition assays 
for the receptors of rat brain using the agonist [3H]CCPA 
and the antagonist [3H]DPCPX as radioligands. NECA, 
CPA, and .N8-[(R)-(-)-1-methyl-2-phenethyl]adenosine 
(R-PIA) were used as reference compounds. Functional 
activity at adenosine receptors was determined in adeny-
late cyclase assays by measuring A1 receptor-mediated 
inhibition in rat fat cell membranes and A2 receptor-me-
diated Stimulation in human platelet membranes.1& 
(13) Nair, V.i Richardson, S. G. Modification of nucleic acid bases 
via radical intermediates: synthesis of dihalogenated purine 
nucleosides. Synthesis 1982, 67o-672. 
(14) Lohse, M. J.i Elger, B.i Lindenbom-Fotinos, J.i Klotz, K.-N.i 
Schwabe, U. Separation of solubilized A2 adenosine receptors 
of human platelets from non-receptor [8H]NECA binding Bites 
by gel filtration. Naunyn-Schmiedeberg's Arch. Pharmacol. 
1988, 337, 644;8. 
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Affinities of 2-alkynyladenosines for the A2 receptors (Table ll) were in the range of 2-40 nM for both receptor 
preparations. In the case of the rat striatal receptors 
highest affmities were found for chain lengths of six and 
seven (compounds 2b and 2c), whereas for the human 
platelet receptors the highest affmities were found for the 
shortest chain lengths (compounds 2a and 2b). All com-
pounds had an A1 receptor affmity (high-affinity compo-
nent) of about 20 nM, regardless of the radioligand used. 
As a consequence, most compounds were moderately 
A2-selective (Table ll). The A2 selectivity was highest for 
a chain length of seven in the case of the rat striatum 
receptor ( -10-fold), and a chain length of five in the case 
of the human platelet receptor (2-3-fold). Shortly after 
a preliminary presentation of our results, 1 Abiru et al.11c 
reported binding data for compounds 2b and 2d. Their 
data agree reasonably with our data: there is a trend 
toward lower A1 affinities and higher A2 affmities, so that 
in their report A2 selectivity is somewhat higher. We think 
these are just variations between laboratories, since also 
the reference compounds showed the same trend, including 
their K n values for the radioligand. 
A very similar pattem was observed in adenylate cyclase 
assays comparing A1 receptors in rat fat cells with A2 re-
ceptors in human platelets (Table 111). Again, all com-
pounds bad identical affinities for A1 receptors (IC50 values 
of 2-3 ~M), but compounds with shorter chain lengths had 
higher aftinities for the platelet A2 receptors. Remarkably, 
a1l 2-alkynyladenosines 2a-d were only 6Q-70o/o effective 
(Emu, Table III), resulting in partial agonists at A2 re-
ceptors. The A2 selectivities calculated from adenylate 
cyclase studies (Table llij were about 10-fold higher than 
those determined by radioligand binding. This phenom-
enon has been observed previously by other groups as weil 
as ourselves. 5.7 It appears tobe due tirstly to the previously 
reported discrepancy between the high-affmity state of A1 
receptors for agonists and the corresponding IC50 values 
in inhibiting adenylate cyclase18-a difference much less 
pronounced for A2 receptors-and secondly to complexities 
in functional assays as a consequence of receptor reserves.l7 
The A2 selectivity was again highest for the shortest chain 
length. 
In order to improve this A2 selectivity, the corresponding 
2-alkynyl derivatives of NECA Sa-d were synthesized and 
tested (Tables II and lll). The overall pattem of results 
are similar to the one obtained above, but the A2 selectivity 
was indeed improved. This resulted in compounds Sb and 
Sc that showed an almost 40-fold selectivity for the A2 
receptors of rat striatum compared to A1 receptors of rat 
brain. Compound Sb also had a lü-20-fold selectivity for 
the A2 receptors of human platelets. A 3Q-45-fold selec-
tivity for platelet A2 receptors compared to A1 receptors 
was found for compounds Sa-c in adenylate cyclase studies 
(Table 111). 
Platelet aggregation studies confll'med the previous re· 
sults. 2-Hexynyl-NECA (Sb) was the most active inhibitor 
of ADP-induced platelet aggregation with an IC50 value 
of 50 nM, compared to the parent compound NECA with 
(15) Klotz, K.-N.; Cristalli, G.i Grifantini, M.; Vittori, S.; Lohse, M. 
J. Photoaffmity labeling of A1-adenosine receptora. J. Biol. 
Chem. 1986, 260, 14659-14664. 
(16) Lohae, M. J.i Klotz, K.-N.i Schwabe, U. Agonist photoaffmity 
labeling of A1 adenosine receptors: persistent activation re-
veals spare receptors. Mol. Pharmacol. 1986, 30, 403-409. 
(17) Lohse, M. J.; Klotz, K.-N.j Schwabe, U. Mechanisma of A2 
adenosine receptor activation. I. Blockade of A2 adenosine 
receptors by photoaffmity labeling. Mol. Pharmacol. 1991, 39, 
517-523. 
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Table 11. Competition of the 2-Alkynyl Derivatives of Adenosine and NECA for RadioUganda at Al and A2 Receptors 
N~N 
RC=t ,_l ~ ,.) 
~ 
HO OH 
A2 selectivity 
Al [3H]DPCPX (KIAl/ KIA2) 
high low Al [3H]CCPA A2 [
3H]NECA DPCPX/ CCPA/ 
compd R Rl affmity affmity Ki (nM)0 striatum platelet striatum striatum 
2a (CH:J2CHa CH20H 16.0 849 21.5 16.4 7.3 1 1 
lO.o-25.5 528-1380 11.2-41.6 8.o-33.8 2.6-20.6 
2b (CH:JaCHa CH20H 12.5 633 15.9 3.6 8.1 3 4 
5.6-27.9 258-1580 4.7-53.2 2.2-5.9 3.8-17.4 
2c (CH:J4CHa CH20H 32.2 1216 28.4 2.8 20.8 11 10 
13.4-77.5 777-1910 17.9-45.2 1.9-4.2 17.4-24.9 
2d (CH:JaCHa CH20H 19.6 823 25.2 6.3 39.9 3 4 
6.5-59.1 484-1400 11.3-56.6 4.2-9.5 10.9-146 
8a (CH:J2CHa CONHEt 33.0 1620 40.8 19.5 12.6 2 2 
18.o-60.0 1150-2260 27.2-61.1 4.1-93.3 4.2-37.9 
Sb (CH2)aCHa CONHEt 136 3160 43.9 3.8 5.7 36 12 
95-195 142o-7030 38.1-50.6 1.5-9.9 4.3-7.5 
8c (CH2).CHa CONHEt 171 2910 89 4.7 37.1 36 19 
146-201 1060-7990 69-114 2.4-9.3 17.3-79.5 
8cl (CH~t)aCHa CONHEt 67 2940 64.4 14.8 159 5 4 
27.()-164 204o-4240 40.5-102.3 8.2-26.7 59-429 
NECA 11 650 8.2 22 •70 0.5 0.4 
7.o-17 42Q-1000 6.2-10.9 2o-25 55-89 
R-PIA 1.0 200 1.3 730 1700 0.001 0.002 
0.8-1.3 160-250 1.1-1.6 69o-770 llOQ-2600 
CPA 0.8 130 0.8 2000 2400 0.0004 0.0004 
0.5-1.3 9()-190 0.6-1.1 14Q0-2900 130Q-4400 
°For Al receptors K1 values were determined from competition for [8H]DPCPX (antagonist) and [3H]CCPA (agonist) binding at rat brain 
membranes. K1 valuea for A2 receptors were determined at rat striatal membranes in the presence of 50 nM CPA and at solubllized 
receptors from human platelet membranes. Data are means from three to six independent experiments with 950J'o confidence limita. 11 A2 
selectivity ratios were calculated with high-affmity K1 values from competition for [3H]DPCPX binding at rat brain membranes and K1 
values from competition for [8H]NECA binding at rat atriatal membranes. For comparison A2 selectivity was also determined with K 1 values 
from competition for [3H]CCPA binding and [3H]NECA binding. 
Table 111. Effecta of the 2-Alkynyl Derivatives of Adenosine and NECA on Adenylate Cyclase0 
NS::N 
RC=tJ._N N) 
~ 
HO OH 
Al A2 
compd R R1 IC50, nM EC50, nM A2 select (IC50/EC50) Eruz,% 
2a (CH2)aCH8 CH20H 3000 127 24 65 
1150-7840 95-171 
2b (CH2)3CH3 CH20H 2300 128 19 65 
132Q-4000 90-182 
2c (CH2)4CH3 CH20H 3380 414 8 65 
12Q0-9620 289--692 
2d (CH2)aCHa CH20H 2910 681 4 65 
103o-8200 24o-1930 
Sa (CH2hCHa CONHEt 2700 62 « 100 
201Q-3630 38-100 
Sb (CH2)aCHa CONHEt 4380 106 42 100 
199o-9640 48-229 
Sc (CHa).CHa CONHEt 13090 388 34 100 
675o-25400 277-643 
Sd (CH2)aCHa CONHEt 13500 585 23 100 
7900-23100 479--714 
0 All compounds inhibited adenylate cyclase via Al receptors in rat fat cell membranes to the same degree as the full agonist CCPA, and 
the maximalinhibitionwas 45 • 4.3% (n ~:~~ 9, :i:SEM). The maximal NECA stimulation of adenylate cyclase via A2 receptora in human 
platelet membranes amounted to 319 :l: 16% (n = 7, :i:SEM). Compounds 2a-d are only partial agonists (Emu= 65%), wbereas 8a-d are 
full agonists (Emu. a 100%). Valuea are means and SEM's or 95% confidence limits of three to four independent determinations. 
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Figure 1. Dose-response curves of inhibitory effect of 2-hexy-
nyl-NECA <•> and NECA (C) on human platelet aggregation 
induced by ADP. Data represent means of at least three inde-
pendent determinations. 
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Figure 2. Intluence of methylene groups in the chain of com-
pounds Sa-d on A2 selectivity. Comparison of A2 selectivity in 
the binding of DPCPX/striatum (e), CCPA/striatum (0), 
DPCPX/platelet (•), and CCPA/platelet (C). 
an IC50 of 500 nM (Figure 1). 
The compounds described here seem to be capable not 
only of distinguishing between A1 and A2 receptors, but 
also between the A2 receptors of rat brain and human 
platelets (Figure 2). 2-Heptynyl-NECA (8c) and 2-octy-
nyl-NECA (8cl) have about a 10-fold higher affinity for the 
rat striatal A2 receptor. Further studies will have to ad-
dress the question whether these are only species differ· 
ences, or whetber they represent true A2 receptor subtypes. 
Agonist& with high affmity for A2 receptors have already 
been described by Bridges et al.188 These are adenosine 
and NECA derivatives With bulky N6-substituents, in 
particular diphenylethyl substituent.s.18b In a direct com-
parison in our laboratory, these compounds bad only little 
if any A2 receptor selectivity (data not shown). Attempts 
to increase ~ selectivity by the combination of appropriate 
modifications at N6 and C5' were not very successful.19 
(18) (a) Bridges, A. J.; Moos, W. H.; Szotek, D. L.; Trivedi, B. K.; 
Bristol, J. A.; Heffner, T. G.; Bruna, R. F.; Downs, D. A. NS-
(2,2-Diphenylethyl)adenosine a novel adenosine receptor 
agonist with antipsychotic-like activity. J. Med. Chem. 1987, 
30, 17~1711. (b) Bridges, A. J.; Bruns, R. F.: Ortwine, D. F.; 
Priebe, S. R.; Szotek, D. L.; Trivedi, B. K. NS-[2·(3,5-Dimeth· 
oxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uro-
namide derivatives. Novel adenosine agonists with both high 
affinity and high selectivity for the adenosine A2 receptor. J. 
Med. Chem. 1988, 31, 1282-1285. 
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Williams and co-workers11 have recently described a series 
of substituted 2-am.ino derivatives of NECA that show 
even higber selectivity for A2 receptor, but have at least 
2-fold lower aff'mities than compounds 8b and 8c described 
here. The high affmities of the compounds described here 
together with reasonable selectivities should make them 
useful tools for the characterization of adenosine receptors. 
Experimental Section 
Chemistry. Melting points were determined with a Büchi 
apparatus and are uncorrected. 1H NMR spectra were obtained 
with a Varian VX 300 MHz spectrometer. IR spectra were re· 
corded on a Perkin-Eimer Model 297 spectrophotometer. TLC 
were carried out on pre-coated TLC plates witb silica gel60 F-254 
(Merck). For column chromatography, silica gel60 (Merck) was 
used. Microanalytical results are within :1:0.4% of theoretical 
values. 
Preparation of 2-Alkynyladenosines (2a-d). To a solution 
of 2·iodoadenosine13 (1) (1.27 mmol) in 10 mL of dry acetonitrile 
and 10 mL of triethylamine under an atmosphere of N2 were 
added 18.6 mg (0.0976 mmol) of cuprous iodide, 12 mg (0.0672 
mmol) of PdC12, and 39 mg (0.149 mmol) of triphenylphosphine. 
To the mixture was added the appropriate terminal alkyne (6.3 
mmol), and the reaction mixture was stirred. under an atmosphere 
of N2 at room temperature for 24 h. The solvent was removed 
in vacuo, and the residue wu chromatographed on a silica gel 
column, eluting with a suitable mixture of solvent& (Table I) to 
give 2a-d as chromatographically pure solids. All of tbe spectral 
data for the compounds were compatible with the structures. 
Preparation of 2-Alkyny~denosiDe-&'·N -ethyluronamides 
(8a-d). To a solution of N-ethyl·1'·deoxy-1'-(6·amino-2-iodo-
9H-purin-9-yl)-ß·D-ribofuranuronamide (7) (0.58 mmol) in 10 mL 
of dry acetonitrile and 5 mL of triethylamine under an atmosphere 
of N2 were added 8.5 mg (0.0446 mmol) of cuprous iodid~, 5.5 mg (0.0308 mmol) of PdC12, and 17.8 mg (0.069 mmol) of tri-
phenylphosphine. To the mixture was added the appropriate 
terminal alkyne (2.9 mmol), and the reaction mixturewas stirred 
under an atmosphere of N2 at room temperature for 16 h. The 
solvent was removed in vacuo, and the residue was chromato-
graphed on a silica gel column, eluting with a suitable mixture 
of solvent& (Table I) to give Sa-d as chromatographically pure 
solids. All of the spectral data for the compounds were compatible 
with the structures. 
6-Amino-2-iodo-9·(2',3'·0 ·hopropylidene·ß·D·ribo· 
furanosyl)-9H-purine (3). To a solution of2 g (5.08 mmol) of 
2-iodoadenosine (1)13 in 100 mL of acetonewas added 9.6 g of 
p·toluenesulfonic acid. The reaction mixture was stirred at room 
temperature for 1 h and then, after the addition of 15 g of 
NaHC03, stirred again for 3 h. The solid was removed and washed 
two times with EtOAc, and the filtrate was concentrated to 
dryness. The residue was tlash chromatographed on a silica gel 
column, eluting with CHC13-MeOH (99:1) to give 1.62 g (74%) 
of 3 as a solid: mp 185-187 °C; 1H NMR (Me~O-de) 61.33 and 
1.54 (s, 3 H each, C(CH3h), 3.53 (m, 2 H, CH2·5'), 4.19 (m, 1 H, 
H-4'), 5.07 (t, 1 H, OH), 4.93 (m, 1 H, H-3'), 5.27 (m, 1 H, H-2'), 
6.05 (d, J = 2.5 Hz, 1 H, H-1'), 7.76 (s, 2 H, NH2), 8.28 (s, 1 H, 
H-8). Anal. (C13H18IN60,) C, H. N. 
1'-Deoxy-1'·(6-amino-2-iodo-9H-purin-9-yl)-2',3'·0·i&o· 
propylidene·ß·D·ribofuranuronic Acid (4). To a stirred so-
lution of 1.6 g (3. 7 mmol) of 3 in 200 mL of H20 were added 0.60 
g of KOH and, dropwise, a solution of 1.70 g (10.8 mmol) of 
KMn04 in 50 mL of H20. The mixture was set aside in the dark 
at room temperature for 20 h. The reaction mixture was cooled 
to 5-10 oc and then decolorized by a solution of 4 mL of 30% 
H20 2 in 16 mL of water, while the temperature was maintained 
under 10 °C using an ice-salt bath. The mixture was filtered 
through Celite, and the filtrate was concentrated in vacuo to about 
15 mL and then acidified to pH 4 with 2 N HCl. The resulting 
precipitate was filtered off and successively washed with water, 
(19) Olsson, R. A.; Kusachi, S.; Thompson, R. D.; Ukena, D.; Pad-
gett, W.; Daly, D. T. N6-Substituted N-alkyladenosine-5'· 
uronamides: bifunctionalligands baving recognition groups for 
A 1 and A2 adenosine receptors. J. Med. Chem. 1986, 29, 
1683-1689. 
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acetone, and ether to give 1.26 g (76%) of 4 as a white solid: mp 
187-190 °C; IR "mu 1590, 1640 cm-1 (COOH); 1H NMR 
(Me2SO-d8) 61.33 and 1.49 (s, 3 H each, C(CH3h), 4.64 (s, 1 H, 
H-4'), 5.35 (d, J 3,,'J/ = 5.6 Hz, 1 H, H-3'), 5.41 (d, J2'.3' = 5.6 Hz, 
1 H, H-2'), 6.23 (a, 1 H, H-1'), 7.53 (s, 1 H, COOH), 7.67 (a, 2 H, 
NH2), 8.17 (a, 1 H, H-8). Anal. (C13H1~IN605) C, H, N. 
1'-Deosy-1'-(6-amino-2-iodo-98 -purin-9-yl)-ß-n-ribo-
furanuronic Acid (5). A solution of 1.72 g (3.85 mmol) of 4 in 
80 mL of 50% HCOOH was atirred at 80 °C for 1.6 h. The 
reaction mixture was evaporated in vacuo, the residue was dis-
aolved in water, and the solution was evaporated. This process 
was repeated several times untll there was no odor of formic acid 
in the residue. Recryatallization from water yielded 1.33 g (86%) 
of 5 as a white solid: mp 217-220 °C dec; 1H NMR (Me2SO-d6) 
6 4.28 (m, 1 H, H-3'), 4.41 (d, J = 2.1 Hz, 1 H, H-4'), 4.81 (m, 1 
H, H-2'), 5.95 (d, J = 6.7 Hz, 1 H, H-1'), 7.78 (s, 2 H, NH:z), 8.38 
(s, 1 H, H-8), 12.98 (br s, 1 H, COOH). Anal. (CtoH101N60 5) C, 
H,N. 
Ethyl 1'-Deosy-1'·(6-amlno-2-iodo-98 -purln-9-yl)·ß-D· 
ribofuranuronate (6). To a cooled (6 °C) and stirred Solution 
of 1.29 g (3.17 mmol) of 5 in 150 mL of absolute ethanol was added 
dropwise 1.16 mL of ice-cooled SOC12• The mixturewas stirred 
at room tempert!ture overnight and then brought to pH 8 with 
aaturated aqueous NaHC03• The mixture was flltered, and the 
rlltrate was concentrated in vacuo. Recrystallization of the residue 
from water-ethanol (1:1) gave 900 mg (65%) of 6 as a white solid: 
mp 221-223 °C dec; IR vmu 1728 cm-1 (COOEt); 1H NMR 
(Me~O-ds) 6 1.21 (t, 3 H, CH2CH3), 4.18 (q, 2 H, CH2CH3), 4.34 (m, 1 H, H-3'), 4.47 (s, 1 H, H-4'), 4.58 (m, 1 H, H-2'), 5.96 (d, 
J = 6.7 Hz, 1 H, H-1'), 7.74 (s, 2 H, NHz), 8.33 (s, 1 H, H-8). Anal. 
(C12Ht~IN&06) C, H, N. 
N-Ethyl-1'-Deoxy-1'-(6-amino-2-iodo-98-purin-9-yl)-ß-n-
ribofuranuronamide (7). A mixture of 620 mg of 6 and 18 mL 
of dry ethylamine was atirred at -20 °C for 3 h and then at room 
temperature overnight. The reaction mixture was dlluted with 
absolute ethanol, and the precipitated product was flltered off 
and wa&hed with dry ether to give 530 mg (85%) of 7 as a pure 
solid: mp 232-234 °C; IR "mu 1637, 1560 cm-1 (C=O, amide); 
1H NMR (Me2SO-ds) ß 1.06 (t, 3 H, CH2CH3), 3.28 (m, 2 H, 
CH2CHs), 4.16 (m, 1·H, H-3'), 4.31 (d, J = 2.1 Hz, 1 H, H-4'), 4.58 (m, 1 H, H-2'), 5.91 (d, 1 H, J = 7.3 Hz, H-1'), 7.79 (a, 2 H, NH2), 
8.15 (t, 1 H, NH), 8.40 (s, 1 H, H-8). Anal. (C12H11;IN80~) C, H, N. 
Biological Studies: Membrane Preparation. Membranes 
from rat br~p and rat atriatum were prepared as deacribed.20 
Human platelet membranea were prepared according to the 
method of Hoffman et al. 21 A2 receptors from platelet membranes 
were solubilized as described recently.14 Rat fat cells were isolated 
as described by Honnor et al.,22 and their membranes were pre-
pared according to MeKeel and Jarett.23 
(20) Lohae, M. J.; Lenschow, V.; Schwabe, U. Two affmity states 
of Ri adenosine receptors in brain membranes: analysis of 
guanine nucleotide and temperature effecta on radioligand 
binding. Mol. Pharmacol. 1984,26, 1-9. 
(21) Hoffman, B. B.; Michel, T.; Brenneman, T. B.; Lefkowitz, R. 
Interactions of agonists with platelet a 2-adrenergic receptors. 
J. Endocrinol. 1982, 110, 926-932. 
(22) Honnor, R. C.; Dhillon, G. S.; Londos, C. Cyclic AMP and 
lipolyais in rat adipocytes. Cell preparation, manipulation and 
predictability in behavior. J. Biol. Chem. 1985, 260, 
15122-15129. 
(23) McKeel, D. W.; Jarett, L. Preparation and characterization of 
a plasma membrane fraction from isolated fat cells J. Gell. 
Biol. 1970, 44, 417-432. 
Cristalli et al. 
Radioligand Binding Aasays. Radioligand binding at A1 
receptors from rat brain membranes was measured as deacribed 
in detail for the antagonist [3H]DPCPX24 and the agonist 
[3H]CCPA.e [SH]NECA was used to measure A2 receptor binding 
in rat striatal membranea, according to the procedure of Bruns 
et al.,7 in a total value of 250 ~L containing 50"' of protein. A1 
receptor was saturated with 50 nM cyclopentyladenosine. Binding 
to solubilized A2 receptors from human platelets was performed 
with [3]NECA as described.14 
Adenylate Cyclase Assay. Inhibition of adenylate cyclase 
activity via A1 receptors was measured in rat fat cell membranes 
in the presence of 10 J.'M forskolin, and stimulation of adenylate 
cyclase via A2 receptors was determined in human platelet 
membranes.15 
Data Analysis. Concentration-response curves containing 
at least aeven different concentrations in duplicate were fitted 
by nonlinear regression to the Hili equation as described.18 
Binding data were analyzed by the curve-fitting program SCATFlT 
according to a one-site model.26 A two-aite modelwas assumed 
if the fit was significantly improved (p < 0.01, F test). 
Platelet Aggregation Assay. Platelet aggregation was 
meaaured by modification of the method of Born and Cross~.28 
using a Platelet Aggregation Profiler Model Pap-3 (Bio Data 
Corp.). The aggregative agent ADP was purchased from Sigma 
Chemical Co. Blood was obtained by venipuncture in the forearms 
of apparently healthy humans and collected in polyethylene tubes 
containing a 1:9 volume of 3.8% sodium citrate. Platelet-rich 
plasma (PRP) was obtained by centrifugation at 1200 rpm for 
15 min, while platelet-poor plasma (PPP) was obtained by cen-
trifugation at 4500 rpm for 20 min. 
A 20-J.'L aliquot of the te&t sample, dissolved in 0.6% of DMSO 
in water, was added to a cuvette containing 470 J.'L ofPRP, and 
a 20 J.'L aliquot of 0.5% of DMSO in water was added to the test 
control. The cuvette was placed in the aggregation meter and 
allowed to incubate at 37 °C for 5 min, alter which 10 J.'L of 2.5 
x 10-s ADP (final concentration) was added to the PRP. 
The percent inhibition of aggregation by a test compound was 
calculated by dividing the maximal deflection in the optical density 
curve in the presence of the compound by that observed in the 
control and then multiplying by 100. Data represent meana of 
at least three independent determinations. 
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